Zyversa TherapeuticsZVSA
13F holders, Q2 2025 (June 30)6holders −1
1new positions
2sold out
$0.68avg. 13F price*
At the end of Q2 2025, 6 institutions reported holding Zyversa Therapeutics Inc. (ZVSA) in their 13F filings, down 1 from Q1 2025. 1 opened new positions and 2 sold out. The largest holders were UBS Group AG ($27K), Geode Capital Management, LLC ($15K) and Tower Research Capital LLC (TRC) ($3K).
- Company
- Zyversa Therapeutics Inc.
- CUSIP
- 98987D300
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $186 |
| Exits | 2 | $11K |
All 13F filers, Q1 2025 → Q2 2025: 13,719 shares bought and 17,528 shares sold, net −3,809 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| UBS Group AG | 0.00% | Add +38.7% | 39,280 | $27K |
| Geode Capital Management, LLC | 0.00% | No change | 21,706 | $15K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +110.0% | 4,525 | $3K |
| Citigroup Inc. | 0.00% | New | 274 | $186 |
| SBI Securities Co., Ltd. | 0.00% | Add +202.0% | 151 | $102 |
| Bank of America Corp. | 0.00% | Add +18.9% | 132 | $90 |
"% of holder's portfolio" is ZVSA's weight in each manager's 13F, not the share of Zyversa Therapeutics Inc. the manager owns.